Division 1 or Division 8? Canada's New Non-Prescription Drug Authorization Guidance, Decoded

On 31 July 2026, Health Canada's Natural and Non-prescription Health Products Directorate published a complete new guidance suite on how to obtain market authorization for a non-prescription drug. For anyone bringing a non-prescription drug to the Canadian market, the single most important decision it clarifies is this: is your product a Division 1 drug or a Division 8 drug? Get that answer wrong and you file the wrong application type, pay the wrong fee, and risk a rejected or refiled submission that costs months.

What changed on 31 July 2026

Health Canada issued a six-part guidance covering an Overview, Getting Started, the Division 1 versus Division 8 decision, Division 1 application guidance, Division 8 submission guidance, and an explanation of technical elements. Nothing in the underlying law changed. What changed is clarity. The guidance sets out, in one place, how sponsors are expected to classify a product, which application types are available in each division, how submission classes and fees are assigned, and the administrative elements a filing must contain. For companies that have relied on informal precedent or a consultant's memory, the guidance turns an implicit decision into a documented one.

Division 1 vs Division 8: the core distinction

A Division 1 drug is authorized under Part C, Division 1 of the Food and Drug Regulations. It receives a DIN and does not require a Notice of Compliance. A Division 8 drug is a new drug, authorized under Division 8 of the Food and Drug Regulations. It requires a Notice of Compliance before it can be sold, and it also receives a DIN. The pivotal question is whether your product is a new drug. The definition of a new drug sits at section C.08.001 of the Food and Drug Regulations, and it is broad: a drug can be new because of its active ingredient, its combination, its dosage form, its strength, or a new use, even if each component is individually well known.

In practice, a product that fully meets an accepted labelling standard or a Category IV Monograph is generally a Division 1 drug. A product that departs from those accepted conditions, or that has no applicable standard, is likely a new drug that belongs in Division 8. The table below summarizes the split.

The submission types at a glance

Once you know your division, the available application types follow. A DINA is a DIN application for a product that attests to a labelling standard or an accepted standard. A DINF is a DIN application for a product that fully meets a Category IV Monograph, which sets out permissible conditions of use and labelling for well-characterized products such as certain antiperspirants, medicated skin care, and sunscreens. On the Division 8 side, an NDS is a full New Drug Submission and an ANDS is an Abbreviated New Drug Submission that compares a generic product to a Canadian reference product. Post-authorization changes to a Division 8 drug are filed as an SNDS or SANDS.

Submission classes, fees, and the missed-standard credit

Direct answer: your submission class drives your fee, and where a product could fit more than one class, Health Canada applies the class with the highest associated fee. Sponsors should map fees before filing, not after. The fees for the examination of a submission are published and vary widely between a DIN application and a full New Drug Submission. There is a meaningful protection built into the fee framework: when Health Canada does not meet its performance standard for a review, the fee framework provides for a partial remission, commonly 25 percent, of the fee paid. Small business mitigation may also reduce fees for eligible companies. None of this removes the need to classify correctly first, because the wrong class means the wrong fee and, often, a refiling.

The six mandatory administrative elements

Every filing, regardless of division, must contain a common set of administrative elements. Missing one is a frequent cause of a screening deficiency, which stops the clock before the science is even reviewed. The guidance lists them clearly.

Five classification traps that cost sponsors months

1. Relying on the New Drug List

The New Drug List is not comprehensive and is no longer updated. A product absent from it is not automatically a Division 1 drug. Classification turns on the definition of a new drug at C.08.001, not on whether the product appears on a list. Treating the list as authoritative is one of the most common and most costly errors.

2. Sloppy Drug Product Database searching

A precedent search in the Drug Product Database only helps if it is done properly. Search by active ingredient, strength, dosage form and route, and check whether the precedent was authorized as a Division 1 or Division 8 product. A single matching brand name proves nothing on its own.

3. Assuming an over-the-counter product cannot be a new drug

Non-prescription does not mean not new. A familiar active ingredient in a new combination, a new strength, a new dosage form, or with a new indication can still be a new drug under C.08.001 and belong in Division 8. Some products are also out of scope of the non-prescription pathway entirely, including certain ethical drugs such as nitroglycerin and epinephrine.

4. Combination products

A combination of two well-known actives is a classic Division 8 trigger. Even where each ingredient has a Category IV Monograph, the combination may not, which pushes the product into new drug territory and an NDS.

5. Co-packaged kits

Kits that co-package a drug with a device, or two drugs together, raise classification and licensing questions that a single-product analysis misses. Map each component and its pathway before you assume a simple DINA will do.

After authorization: what Division 8 holders still owe

Classification does not end at approval. A Division 8 drug remains subject to both Division 1 post-market requirements, such as adverse drug reaction reporting, and Division 8 requirements, such as filing supplements for formulation changes that need approval. This dual burden is exactly what Health Canada's proposed low-risk drug Ministerial Order aims to ease for certain low-risk products, by allowing a Division 1 route for products that would otherwise sit in Division 8. Sponsors watching that pathway should still plan for the full Division 8 obligations unless and until an exemption applies to their product.

A worked example: where sponsors get the division wrong

Consider a company that wants to launch a topical analgesic cream combining two well-known active ingredients, each with its own Category IV Monograph. The team assumes that two monographed actives means a simple DINF. In practice, if no monograph covers the specific combination, the product is very likely a new drug under C.08.001 and belongs in Division 8 as a New Drug Submission with supporting safety and efficacy evidence. A sponsor that files a DINF here will usually be screened out, lose the review time already spent, and have to refile as an NDS at a higher fee. The lesson is simple: monographs apply to the exact product they describe, and a novel combination almost always breaks the Division 1 assumption. A short classification review at the start would have caught it.

Disinfectants, antiseptics and the DIN pathway

Surface disinfectants and antiseptic skin products sit inside this same framework and are a common source of classification confusion. Hard-surface disinfectants are drugs in Canada and require a DIN, and many follow a Division 1 route where they meet an accepted standard or monograph. Human-use antiseptics have their own guidance and evidence expectations. The key point for any sponsor in the self-care and disinfectant space is the same as for oral and topical drugs: confirm which accepted standard or monograph applies, decide the division from the regulation, and only then choose the application type. Treating a disinfectant as a formality rather than a regulated drug is a fast route to a rejected filing.

Compliance checklist

Before you file a non-prescription drug application, confirm each of the following.

• You have applied the C.08.001 new drug definition to your specific active, combination, strength, dosage form and indication.
• You have confirmed whether an accepted labelling standard or Category IV Monograph fully covers your product.
• You have chosen the correct application or submission type: DINA, DINF, NDS or ANDS.
• You have mapped the submission class and fee, allowing for the highest-fee rule where more than one class could apply.
• You have assembled all six administrative elements, including the labels and packages certification form even if no labels are provided.
• You hold or have applied for a Drug Establishment Licence covering your licensable activities.
• You have a post-authorization plan for the obligations your division carries, including adverse reaction reporting.

Common mistakes

• Classifying by product name rather than by regulation. The label wording does not decide the division; the new drug definition does.
• Filing a DINF for a product that does not fully meet the monograph. Partial compliance is not compliance; any deviation usually means Division 8.
• Underbudgeting the fee. A misclassified NDS costs far more than a DINA, and the highest-fee rule can surprise unprepared sponsors.
• Omitting the labels and packages certification form. It is required even when no labels accompany the filing, and its absence triggers a screening deficiency.
• Forgetting the establishment licence. Market authorization and the Drug Establishment Licence are separate requirements; you need both to sell.

Frequently asked questions

Do I need a DIN or a Notice of Compliance for my non-prescription drug?

Every non-prescription drug needs a DIN. Only a Division 8 drug, that is a new drug, also needs a Notice of Compliance. If your product fully meets an accepted standard or a Category IV Monograph, it is a Division 1 drug and a DIN is sufficient.

What is the difference between Division 1 and Division 8?

Division 1 covers drugs authorized by a DIN under Part C, Division 1 of the Food and Drug Regulations, without a Notice of Compliance. Division 8 covers new drugs, which need a Notice of Compliance based on a full evidence package. The dividing line is whether your product is a new drug under C.08.001.

What is a DINF application?

A DINF is a Drug Identification Number application for a product that fully meets a Category IV Monograph. It is a Division 1 route used for well-characterized products such as certain sunscreens and medicated skin care that match the monograph's conditions of use and labelling.

Is my product a new drug if the active ingredient is already sold in Canada?

It can be. A drug can be new because of a new combination, strength, dosage form or use, even when each element is individually familiar. The C.08.001 definition looks at the whole product, not just the active ingredient.

How are the fees decided if my product fits more than one class?

Where a product could fall into more than one submission class, Health Canada applies the class with the highest associated fee. If Health Canada misses its performance standard for the review, the fee framework provides for a partial remission, commonly 25 percent.

Can I rely on the New Drug List to decide?

No. The New Drug List is not comprehensive and is no longer updated. Absence from the list does not make a product a Division 1 drug. Base the decision on the regulatory definition of a new drug.

What administrative documents must every filing contain?

A cover letter, the REP regulatory transaction template, the REP product information template, the labels and packages certification form, the applicable DIN or NDS or ANDS certification, and a third-party authorization form where relevant.

Does a Division 8 drug still have Division 1 obligations after approval?

Yes. After a Notice of Compliance, a Division 8 drug carries both Division 1 obligations, such as adverse drug reaction reporting, and Division 8 obligations, such as filing supplements for changes that require approval.

How MFLRC can help

A classification error is one of the most expensive mistakes in the non-prescription drug space, because it is usually discovered only after a filing is screened out. MFLRC gives sponsors a defensible answer before they file. Our regulatory affairs, licensing and import and export team delivers regulatory classification opinions, submission strategy and gap assessments, DINA and DINF preparation, NDS and ANDS project management, REP transaction preparation, labelling review and certification, and post-authorization change management. We work the same drug and natural health product boundary questions every week, from the raw material versus finished product classification question to the low-risk drug Ministerial Order pathway.

Beyond the submission itself, we help you build the quality systems that a Drug Establishment Licence and ongoing compliance require, from licensing simplification on the NHP side to the standard operating procedures that inspections turn on. Explore our pharmaceutical regulatory services to see the full scope.

Conclusion

Health Canada's July 2026 guidance does not change the law, but it removes the excuse for guessing. The Division 1 versus Division 8 decision now has a documented framework, a clear set of application types, a fee logic, and a fixed list of administrative elements. Sponsors who classify carefully, search precedents properly, and assemble a complete filing move through screening faster and avoid the refiling that eats a launch timeline. Sponsors who improvise pay twice. Decide the division first, and let everything else follow from it.

Sources and references

• Health Canada, How to obtain market authorization for a non-prescription drug in Canada (guidance suite, 2026)
• Health Canada, Regulatory overview: non-prescription drugs in Canada, submission information and requirements
• Food and Drug Regulations, Division 8 (new drugs), including the C.08.001 definition
• Health Canada, Non-prescription Drugs: Category IV Monographs
• Health Canada, Fees for the examination of a submission: drugs for human use